WILMINGTON, Del. / Sep 25, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that key data from across its dermatology portfolio, including multiple late-breaking abstracts, will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2024 held September 25-28 in Amsterdam. “We’re excited to present five late-breaking oral presentations at this year’s congress, featuring data... Read More

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024 Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in... Read More

Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a... Read More

WILMINGTON, Del. / Sep 09, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 11,497 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of September 3, 2024, and were approved by the compensation... Read More

Presidential Symposium to feature Phase 3 retifanlimab (Zynyz ® ) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024 Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers Incyte to host an in-person analyst and investor... Read More

Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi ® ) or placebo in combination with lenalidomide and rituximab met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL) Based on these results, Incyte expects to file a supplemental Biologics License Application for tafasitamab in combination with lenalidomide and rituximab in FL by the end of... Read More

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting the approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups Syndax conference call and webcast scheduled for today at 6:00 p.m. ET WILMINGTON, Del. & WALTHAM, Mass. / Aug 14,... Read More

WILMINGTON, Del. / Aug 13, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT) Morgan Stanley 22 nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT) Cantor Global Healthcare Conference on Thursday, September 19,... Read More

WILMINGTON, Del. / Aug 07, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,009 shares of the Company’s common stock to 19 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 1, 2024, and were approved by the compensation committee of... Read More

Total revenues of $1,044 million in the second quarter (Q2'24) (+9% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $706 million in Q2'24 (+3% Y/Y), total patients increased +7% Y/Y; raising the bottom end of full year 2024 guidance to a new range of $2,710 - $2,750 million Opzelura ® (ruxolitinib) net product revenues of $122 million in Q2'24 (+52% Y/Y); continued uptake in atopic dermatitis (AD) and vitiligo in the... Read More

WILMINGTON, Del. / Jul 09, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2024. The schedule for the press release and conference call/webcast is as follows: Q2 2024 Press Release: July 30, 2024 at 7:00 a.m. ET Q2 2024 Conference Call: July 30, 2024 at 8:00 a.m. ET Domestic Dial-In Number:... Read More

WILMINGTON, Del. / Jul 08, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 14,577 shares of the Company’s common stock and stock option awards to purchase an aggregate of 18,149 shares of the Company’s common stock to 27 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date... Read More

WILMINGTON, Del. / Jun 13, 2024 / Business Wire / Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the final results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024. Based on the final count by Computershare Trust Company, N.A., the... Read More

WILMINGTON, Del. / Jun 11, 2024 / Business Wire / Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the preliminary results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024. Based on the preliminary count by Computershare Trust Company,... Read More

WILMINGTON, Del. / Jun 07, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 14,090 shares of the Company’s common stock and stock option awards to purchase an aggregate of 9,238 shares of the Company’s common stock to 17 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and... Read More

Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to patients WILMINGTON, Del. & SAN DIEGO / May 30, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic... Read More

WILMINGTON, Del. / May 21, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmington. This acquisition marks Incyte’s fourth expansion in Delaware since establishing operations in Alapocas in 2014. The new buildings will allow the Company’s U.S.-based teams to be... Read More

WILMINGTON, Del. / May 21, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45 th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. ,... Read More

WILMINGTON, Del. / May 14, 2024 / Business Wire / Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually. "The data being... Read More

Incyte commences Dutch Auction tender offer to repurchase up to $1.67 billion of outstanding common shares WILMINGTON, Del. / May 13, 2024 / Business Wire / Incyte Corporation (Nasdaq:INCY) (the “Company”) today announced that its Board of Directors approved a share repurchase authorization of $2.0 billion. The Company has commenced a modified “Dutch Auction” tender offer to repurchase shares of its common stock for an... Read More

WILMINGTON, Del. / May 02, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve... Read More

Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million Opzelura ® (ruxolitinib) net product revenues of $86 million (+52% Y/Y) in Q1'24; continued uptake in atopic dermatitis (AD) and vitiligo Incyte to acquire Escient Pharmaceuticals and... Read More

EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus... Read More

WILMINGTON, Del. / Apr 11, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024. The schedule for the press release and conference call/webcast is as follows: • Q1 2024 Press Release: April 30, 2024 at 7:00 a.m. ET • Q1 2024 Conference Call: April 30, 2024 at 8:00 a.m. ET • Domestic Dial-In... Read More

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria WILMINGTON, Del. and HONG KONG / Apr 01, 2024 / Business Wire / Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased... Read More

WILMINGTON, Del. / Mar 29, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new... Read More

Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of ruxolitinib cream Results presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting WILMINGTON, Del. / Mar 10, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety... Read More

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis (PN) Results presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting marks Incyte’s first presentation of data in PN WILMINGTON, Del. / Mar 10, 2024 / Business Wire / Incyte... Read More

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura ® ) in hidradenitis suppurativa and povorcitinib (INCB54707) in prurigo nodularis Analyst and investor event to discuss key data presentations scheduled for Monday, March 11, 2024 at 9:00 a.m. PT / 12:00 p.m. ET WILMINGTON, Del. / Mar 04, 2024 / Business Wire / Incyte (Nasdaq:INCY) today... Read More

The Unseen Journey brings to life the often-misunderstood impact of common myeloproliferative neoplasm (MPN) symptoms through AI-generated images developed from the words and experiences of real patients WILMINGTON, Del. / Feb 29, 2024 / Business Wire / Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey , a... Read More

Priority Review acceptance based on positive results of AGAVE-201 study WILMINGTON, Del. / Feb 27, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of... Read More

WILMINGTON, Del. / Feb 15, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 44 th Annual Health Care Conference on Monday, March 4, 2024 at 9:50 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte... Read More

Total FY'23 net product and royalty revenues of $3.7 billion (+14% Y/Y); total FY'23 net product revenues of $3.2 billion (+15% Y/Y) Jakafi ® (ruxolitinib) net revenues of $2.6 billion (+8%) for FY'23; Jakafi net revenues guidance range of $2,690 - $2,750 million for FY 2024 Opzelura ® (ruxolitinib) cream net revenues of $109 million in Q4'23 and $338 million for FY'23, driven by strong demand in atopic dermatitis and the... Read More

Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications WILMINGTON, Del. / Feb 05, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for... Read More

WILMINGTON, Del. / Jan 23, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Press Release: February 13, 2024 at 7:00 a.m. ET Q4 & YE 2023 Conference Call: February 13, 2024... Read More

Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth Company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura ® ) in adults with hidradenitis suppurativa (HS) Overview of early pipeline, including preliminary results from Phase 1 study of INCB123667 (CDK2i), will also be... Read More

WILMINGTON, Del. / Dec 12, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 4, 2024 at 9:30 am (EST) 42 nd Annual J. P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 am (PST) The presentations will be webcast... Read More

Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment Data are featured in the Plenary Scientific Session at the 65 th American Society of Hematology Annual Meeting 2023 Incyte and its partner Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023 WILMINGTON, Del.... Read More

Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines Plenary Scientific Session will feature the full data from AGAVE-201 evaluating axatilimab, an anti-CSFR-1R monoclonal antibody, in patients with chronic graft-versus-host disease (GVHD) Incyte to host an in-person analyst and investor event on Monday, December 11, 2023 from... Read More

Total revenues of $919 million in the third quarter (Q3'23) (+12% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $636 million (+3% Y/Y) in Q3'23, $1.9 billion (+8% Y/Y) YTD 2023, driven by growth in total patients across all indications; tightening full year 2023 guidance to a new range of $2.59 - $2.62 billion Opzelura ® (ruxolitinib) cream net product revenues of $92 million (+141% Y/Y) in Q3'23, $229 million YTD... Read More

WILMINGTON, Del. / Oct 27, 2023 / Business Wire / Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals. Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized for its loyal employees, social responsibility and treating employees with respect.... Read More

WILMINGTON, Del. / Oct 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Securities 5 th Annual Inflammation, Neurology & Immunology (INI) Conference on Tuesday, November 7, 2023 at 1:10 pm (EST) Evercore ISI 6 th Annual HealthCONx Conference on Thursday, November 30, 2023 at 12:30 pm (EST) The presentations will... Read More

WILMINGTON, Del. / Oct 16, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid. "We look forward to sharing data from our oncology portfolio with the scientific community at this year’s ESMO Congress,” said Steven Stein, M.D., Chief... Read More

In the TRuE-AD3 trial, children (age ≥2 to <12 years old) with atopic dermatitis (AD) treated with ruxolitinib cream achieved significant efficacy, as defined by the Investigator’s Global Assessment-treatment success (IGA-TS), following eight weeks of treatment In a second study, treatment with ruxolitinib cream over eight weeks under maximum-use conditions was well tolerated in children (age ≥2 to <12 years) Data were... Read More

WILMINGTON, Del. / Oct 13, 2023 / Business Wire / I ncyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix. “We look forward to sharing data from three oral... Read More

Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years Results were presented in a late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Congress 2023 WILMINGTON, Del. / Oct 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new results of a... Read More

WILMINGTON, Del. / Oct 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today its partnership with actress, singer and songwriter Mandy Moore on Moments of Clarity , an educational initiative highlighting the authentic stories of people living with mild to moderate atopic dermatitis (AD) and their journey to finding... Read More

Longer-term use of povorcitinib resulted in further improvement in total body and facial repigmentation Results were presented in a late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Congress 2023 WILMINGTON, Del. / Oct 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib... Read More

WILMINGTON, Del. / Oct 10, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 31, 2023. The schedule for the press release and conference call/webcast is as follows: Q3 2023 Press Release: October 31, 2023 at 7:00 a.m. ET Q3 2023 Conference Call: October 31, 2023 at 8:00 a.m. ET Domestic Dial-In... Read More

WILMINGTON, Del. / Sep 29, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and... Read More

WILMINGTON, Del. / Aug 22, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023 at 8:45 am (EDT) Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023 at 11:20 am (EDT) Bank of America 2023 Global Healthcare Conference on... Read More

Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023 Opzelura ® (ruxolitinib) cream net product revenues of $80 million (+384% Y/Y) in Q2'23; continued uptake in atopic dermatitis (AD) and vitiligo Two pivotal studies... Read More

Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280 WOBURN, Mass. & WILMINGTON, Del. / Jul 31, 2023 / Business Wire / Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical... Read More

Phase 3 TruE-AD3 Study met its primary endpoint WILMINGTON, Del. / Jul 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura ® ) in children (age ≥2 to <12 years) with atopic dermatitis (AD). The study met its primary endpoint and showed significantly... Read More

WILMINGTON, Del. / Jul 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 1, 2023. The schedule for the press release and conference call/webcast is as follows: Q2 2023 Press Release: August 1, 2023 at 7:00 a.m. ET Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET Domestic Dial-In... Read More

WILMINGTON, Del. / May 25, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the European Hematology Association 2023 (EHA2023) Hybrid Congress held in Frankfurt, Germany, from June 8-11 and virtually from June... Read More

WILMINGTON, Del. / May 23, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 11:20 a.m. (CDT) Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:40 a.m. (PDT) The presentations will be webcast live and can be accessed... Read More

Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development WILMINGTON, Del. / May 08, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across... Read More

Total net product revenues of $693 million in Q1'23 (+14% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023 Opzelura ® (ruxolitinib) cream approved as the first and only treatment for repigmentation of nonsegmental vitiligo in Europe; continued strong U.S. launch in atopic dermatitis and vitiligo... Read More

Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 WILMINGTON, Del. / May 01, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to control pruritus (itching) and reduce disease severity in... Read More

Opzelura ® (ruxolitinib) Cream is the first approved treatment in the European Union (EU) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improved facial and total body repigmentation, sustained and continued improvements with longer duration of treatment WILMINGTON, Del. / Apr 20, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced... Read More

WILMINGTON, Del. / Apr 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 10:40 a.m. (PDT) 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 10:30 a.m. (EDT) The presentations will be webcast live and can be accessed at... Read More

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 BOSTON & WILMINGTON, Del. / Apr 16, 2023 / Business Wire / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the Phase 2 L-MIND study showing that... Read More

WILMINGTON, Del. / Apr 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 2, 2023. The schedule for the press release and conference call/webcast is as follows: Q1 2023 Press Release: May 2, 2023 at 7:00 a.m. ET Q1 2023 Conference Call: May 2, 2023 at 8:00 a.m. ET Domestic Dial-In Number:... Read More

WILMINGTON, Del. & TOKYO / Mar 27, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion (also known as 8p11 myeloproliferative syndrome). MLNs are a rare, aggressive group of... Read More

WILMINGTON, Del. / Mar 23, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). The complete response letter states that... Read More

First regulatory approval for Incyte PD-1 inhibitor based on the results of the POD1UM-201 trial Zynyz is also being studied in additional tumor types and in combination with other Incyte pipeline compounds WILMINGTON, Del. / Mar 22, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz ™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting... Read More

WILMINGTON, Del. / Mar 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation (Session: S042 – Late-Breaking Research: Session 2) at the 2023 American... Read More

WILMINGTON, Del. / Mar 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura ® (ruxolitinib) cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin. These data were presented today in two late-breaking oral presentations (Session:... Read More

WILMINGTON, Del. / Mar 14, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida. “As Incyte continues to advance research in areas where we believe we can have the biggest impact for patients, we look forward to... Read More

IRVING, Texas , March 7, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline. Caris' unique platform combines data from whole exome... Read More

WILMINGTON, Del. / Mar 06, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans. New data from the Phase 3 TRuE-V clinical trial program evaluating the durability and long-term response (up to 104 weeks) of Opzelura ®... Read More

WILMINGTON, Del. / Mar 03, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. The recommendation to stop the study was not due to safety.... Read More

WILMINGTON, Del. / Feb 24, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura™) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “The positive CHMP opinion brings us one... Read More

WILMINGTON, Del. / Feb 16, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company... Read More

WILMINGTON, Del. / Feb 10, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS). These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held... Read More

WILMINGTON, Del. / Jan 24, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Guggenheim Healthcare Talks l Oncology Day on Wednesday, February 8, 2023 at 1:35 p.m. (EST) in New York. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical... Read More

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2022 Press Release: February 7, 2023 at 7:00 a.m. ET Q4 & YE 2022 Conference Call: February 7, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042... Read More

INCA033989, a new anti-mutant calreticulin (CALR)-targeted monoclonal antibody, represents important research milestone in myelofibrosis (MF) and essential thrombocythemia (ET) INCA033989 abstract selected as one of only six ASH plenary presentations INCA033989 clinical trials to begin in 2023 Research highlights Incyte’s discovery capabilities and progress of its LIMBER program evaluating new targets and combinations for... Read More

Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi ® ) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib These studies are... Read More